Objectives. TNF-a inhibitors (TNFIs) have a black box warning for increased risk of serious infection that was based on evidence from studies of adults. Evidence of the association is lacking for children. We aimed to examine the risk of infection posed by TNFIs compared with DMARDs in children with JIA.
Introduction
TNF-a inhibitors (TNFIs), including mAb (e.g. infliximab and adalimumab) and fusion proteins (etanercept), are biological agents used to treat RA and JIA. TNFIs are highly effective for RA and JIA and have been shown in clinical trials to induce disease remission, improve quality of life and enhance physical functioning [13] . The ACR recommends use of TNFIs for patients who have received MTX or LEF for 36 months and whose disease activity remains uncontrolled [4, 5] . In addition, earlier use of TNFIs has been shown to improve short-term clinical outcomes in both RA and JIA [6, 7] . As a result, TNFI use has increased over the past decade [8, 9] .
Although TNFIs are generally safe, growth in their use has resulted in more reports of adverse events. In particular, infections have been the most frequently reported serious adverse event in adult RA patients [10, 11] . However, mixed findings were observed in evaluations of the association between TNFIs and infection in meta-analyses [1214] and observational studies [10, 11, 1519] . Some studies reported increased risk of infection for TNFIs compared with DMARDs [12, 13, 15, 16, 19] , whereas others found no elevated risk [10, 11, 14, 17, 18] . Nevertheless, in 2008, the US Food and Drug Administration (FDA) required TNFI manufacturers to include a black box warning in the product label for serious infections leading to hospitalization or death [20] .
The warning applies to both adults and children, yet most studies evaluating the TNFIinfection association were conducted in adults with RA. Children are a vulnerable population more likely to experience adverse drug events than adults [21] . In addition, the immaturity of their immune system may put children at a higher risk for infection [22] . Unfortunately, clinical and observational studies involving JIA patients have had limited numbers of participants and short follow-up periods [1, 2, 23, 24] .
More definitive evidence is needed for the association between TNFIs and infection in children. The aim of this study was to examine the risk of serious bacterial infection associated with TNFIs in children with JIA.
Methods

Data sources
In this retrospective cohort study, we analysed data from the Truven Health MarketScan Commercial Claims and Encounters database for the period from 1 January 2009 to 31 December 2013. The database contains employerbased health insurance claims for enrollees and their dependants across the USA. Administrative data on patient enrolment; health-care utilization, including hospitalizations and visits to outpatient clinics and emergency departments; medical procedures; costs of services; and pharmacy records are available in the database and for research use [25] . Ethical approval was not required to analyse the data in this study.
Population
The analytical cohort was developed by first identifying children (age <16 years) with JIA who had at least one prescription for a TNFI or DMARD during the study period. JIA was identified using a previously validated algorithm that included International Classification of Disease, ninth version, Clinical Modification codes 714.xx (RA and JIA), 696.0 (PsA) and 720.xx (AS) [26] . Included children were required to have two or more JIA diagnoses within 1 year or one JIA diagnosis coded by a paediatrician or rheumatologist [26] . The date of the first new prescription for a TNFI or DMARD was defined as the index date and included new users who had to have no previous use of either TNFIs or DMARDs 6 months before the index date. In addition, patients were excluded if they met any of the following criteria during the 6 months before the index date: (i) discontinued health plan enrolment; (ii) history of tuberculosis and/or use of medications for tuberculosis; or (iii) history of cancer, transplantation and/or HIV infection.
Exposures
Exposures to TNFIs and DMARDs were identified using National Drug Codes and Healthcare Common Procedure Coding System. DMARDs included MTX, HCQ, SSZ and LEF, and TNFIs included etanercept, adalimumab, infliximab, certolizumab and golimumab. Each included patient was followed from the index date to the first occurrence of infection, disenrolment from the health plan, discontinuation of treatment, a switch between or a combined use of a TNFI and DMARD, or the end of the study period (31 December 2013). The observation time was the time of continuous use of TNFI monotherapy or DMARD monotherapy. Discontinuation of medication was defined as a gap >92 days between the end of one prescription's supply (in days) and the next prescription date. For patients who discontinued their medication, we censored them at the end of the last prescription's days supply before a gap >92 days.
Outcomes
The outcome of interest was the first occurrence of a serious bacterial infection, which was defined as an infection requiring hospitalization. We applied a previously validated algorithm that incorporated 27 infection sites using International Classification of Disease, ninth version, Clinical Modification codes at any diagnosis position in the inpatient claims [27] . If an individual was diagnosed as having an infection at two or more sites on the same date, the major site of infection was identified based on the severity of infection, concomitant diagnoses and procedures recorded. Only 14% of cases of serious infections had more than one site of infection.
High-dimensional propensity score models
We used a high-dimensional propensity score (hdPS) to identify and adjust for a large number of covariates that could confound the association between the exposure and infections [28, 29] . Variables were grouped in dimensions that included outpatient diagnoses, inpatient diagnoses, outpatient procedures, inpatient procedures and outpatient medication use during the 6 months before the index date. Thus, any medical conditions (including previous infection) represented by diagnosis or procedure codes or medication use were examined using the hdPS algorithm. The algorithm calculated and ranked a measure of confounding bias for each variable and selected the 500 top-ranked variables into the propensity score model (see supplementary Table S1 , available at Rheumatology Online). Along with the 500 empirical variables, we included demographic variables (age, gender, geographical location, calendar year of medication use and type of health plan on the index date) and health-care utilization variables (the number of visits to outpatient, inpatient and emergency departments during the 6 months before the index date) in the logistic regression model to calculate the probability of receiving TNFIs (i.e. the propensity score).
Statistical analysis
Demographic information, health-care utilization, comorbidities and concomitant medication use were compared between the TNFI and DMARD groups using Student's unpaired t-test, a 2 test or Fisher's exact test, as appropriate. Crude rates of serious infection (number of events per 100 person-years) and 95% CIs were computed using the Poisson exact method. Specific infection sites were described. A KaplanMeier plot and log-rank test were used to examine the rate of serious infection over time. Cox proportional hazard models were used to estimate the hazard ratios (HRs) for serious infection associated with use of TNFIs compared with DMARDs. The tertile of the propensity score was included in the final Cox model. Analyses stratified by gender were also performed. We also conducted several sensitivity analyses to examine the robustness of our findings, as follows: (i) we adjusted for CS use in a time-varying manner to account for the effect of CSs during follow-up; (ii) we restricted our analysis to children 52 to <16 years of age, which is consistent with the FDA label; (iii) we extended the observation period by 30 and 90 days beyond discontinuation of medication use to capture infections occurring after discontinuation; (iv) we reduced the gap defining treatment discontinuation from 92 to 31 days based on the duration of drug effect [1, 30] ; (v) We excluded patients with SLE, SS or psoriasis 6 months before the index date owing to the fact that patients with autoimmune diseases may have different baseline risk for infection; (vi) we also excluded patients with IBD from (v); (vii) we excluded patients who used HCQ or SSZ in the DMARD group because users of these two medications usually had less severe disease; and (viii) we excluded 1% and 5% of patients with extreme hdPS, respectively.
All analyses were performed using SAS statistical software version 9.4 (SAS Institute, Cary, NC, USA) and STATA 12 (StataCorp, College Station, TX, USA). The Institutional Review Board determined this study to be non-human subject research.
Results
We identified 5497 children with JIA who were prescribed either a TNFI or a DMARD during the study period ( Fig. 1) . After applying the exclusion criteria, the final study cohort consisted of 2495 individuals, including 2013 new DMARD users and 482 new TNFI users.
Baseline characteristics were compared between the TNFI and DMARD groups (Table 1) . TNFI initiators were slightly older than DMARD initiators (mean age: 10.4 vs The covariates were measured in the 6 months before the index date. ED: emergency department; TNFI: TNF inhibitor. 9.9 years); less likely to be female (62.9 vs 70.6%); more likely to have uveitis (12.7 vs 8.8%), asthma (9.1 vs 6.5%) or IBD (9.8 vs 1.4%); and more likely to have a hospitalization attributable to infection (3.1 vs 1.7%) in the 6 months preceding the index date. In contrast, the DMARD group had higher proportions of patients with a history of SLE (1.7 vs 0.4%), NSAID use (60.5 vs 42.7%), CS use (27.9 vs 23.4%) and antibiotic use (38.7 vs 31.1%).
The mean follow-up time was 255 days for the DMARD group and 307 days for the TNFI group. We observed 18 and 11 serious infections in 1405.4 and 404.9 total person-years for the DMARD and TNFI groups, respectively; this resulted in crude rates of 1.28 (95% CI 0.76-2.02) and 2.72 (95%CI 1.36-4.86) serious infections per 100 person-years for these groups ( Table 2 ). The TNFI group had 1.44 more serious infections per 100 personyears than the DMARD group. The crude rate ratio for infection was 2.12 (95% CI: 0.91, 4.74) for TNFIs compared with DMARDs. The higher rate of TNFI-associated serious infection was also reflected in the crude cumulative hazard estimates (log rank test P = 0.0357; Fig. 2 ). In addition, among the patients with infections, the median time to infection was 86 days (interquartile range 37198) for the DMARD group and 91 days (interquartile range 21207) for the TNFI group.
Compared with DMARDs, use of TNFIs was associated with an increased risk of serious bacterial infection (HR = 2.74, 95% CI: 1.14, 6.56) after adjusting for the Table 3 shows specific sites of infection in the TNFI and DMARD users. For both the TNFI and DMARD groups, infections were most commonly observed in the respiratory tract (36.4 and 33.3%), followed by the digestive system (27.3 and 22.2%), other organ systems (which included blood and device-related infections; 18.2 and 22.2%), skin and skin structure (9.1 and 16.7%) and genitourinary system (9.1 and 5.6%).
In the sensitivity analyses (Fig. 3) , the risk estimate became non-significant when we restricted the study cohort to 2 to <16 years of age (HR = 2.53, 95% CI: 0.98, 6.55) and excluded patients with other rheumatoid diseases and IBD (HR = 1.15, 95% CI: 0.28, 4.17). However, we observed a greater infection risk for TNFIs when the gap for defining treatment discontinuation was reduced to 31 days (HR = 3.61, 95% CI: 1.32, 9.87) and when HCQ and SSZ users were excluded from the DMARD group (HR = 3.15, 95% CI: 1.14, 8.67).
Discussion
In a population of commercially insured children with JIA, we found that new use of TNFIs was associated with a 2.7-fold increase in risk of serious bacterial infection compared with new use of DMARDs. This increased risk estimate is consistent with the findings of some RA studies in adults [15, 16] . However, previous studies examining the association between TNFIs and infection in children with JIA had conflicting results. For example, Beukelman et al. [31, 32] Unlike previous studies, we adopted a new-user design for exposure groups. A recent study also examined new use of TNFIs and MTX in children with JIA from the Medicaid database [32] ; however, in their study the use of MTX was considered a time-varying covariate, whereas in our study the effects of MTX were excluded from the TNFI group. Although TNFIs are usually recommended for use in combination with DMARDs, studies have shown that TNFIs are increasingly used early in the JIA disease course [35, 36] and as monotherapy [9, 36] . This new treatment paradigm facilitated our comparison of the two groups, as both consisted of new initiators of therapy. Notably, the black box warning for TNFIs stated that most infections developed when the drugs were used in combination with other immunosuppressants, such as DMARDs or CSs [37] . However, our study provides evidence that TNFI monotherapy is also associated with an Patients could have diagnoses of infections at more than one site at their event hospitalization, and the major site of infection was used based on clinical expert opinion.
increased risk of infection while controlling for CS use and other confounders. In addition, we further confirm the risk of infection associated with TNFI use in children with JIA. In our study, the rates of infection in the TNFI group (2.27/100 person-years) and DMARD group (1.28/100 person-years) were consistent with those observed in other studies of JIA [33, 38, 39] . The likely mechanism by which TNFIs increase the risk of infection is related to the role of TNF in the immune response [40] . Inhibiting the action of TNF prevents the normal immune response, increasing the risk for infections. It is possible that infections are not detected until they become severe because TNFIs impede the usual clinical presentation of high fever and elevated CRP. In addition, use of TNFIs may mimic a primary immunodeficiency that is considered a risk factor for mAb-related infections [41] .
The time to infection (median of 90 days) was short in our study and was similar to findings of previous studies. For example, in the analysis by Davies et al. [33] , 44% (24 of 54) of patients developed a serious infection requiring hospitalization within 6 months of etanercept initiation in children with JIA. A study of adults with RA also reported that the adjusted incidence rate ratio was 4.6 (95% CI: 1.8, 11.9) for TNFIs compared with DMARDs when restricting the follow-up time to the first 90 days [18] . These findings are consistent with the pharmacodynamic properties of TNFIs. The time to therapeutic effect of TNFIs varies by individual patient but is typically rapid; symptom improvement can be seen after two or three doses, and additional improvements over 36 months have been reported. Given these findings, health-care professionals should be vigilant in monitoring for symptoms of infection, especially in the first 36 months of treatment.
Although our results suggest increased risk for infections associated with TNFIs compared with DMARDs, clinicians and patients should consider this risk in light of the benefits of TNFIs. Specifically, TNFIs are highly effective drugs that have been shown to improve symptoms, physical functioning, radiographic progression and quality of life [13] . In order to balance the risks and benefits associated with TNFIs, both the US FDA and the European Medicines Agency have developed risk-mitigation strategies for these biologics, but guidance on risk management for children is lacking [42, 43] . Our findings provide evidence that these agencies could use to adapt risk-management plans for children undergoing TNFI treatment. Such plans could incorporate appropriate screening, monitoring and even withholding of treatment to mitigate the potential harm of TNFIs to children with JIA. The strengths of our study include its use of relatively recent data (200913), use of a new-user design and use of an hdPS approach. However, our findings should be interpreted with consideration of the limitations. In particular, our results are subject to limitations common to studies using administrative claims databases, including potential misclassification of outcomes and exposure. However, we minimized this potential issue by using previously validated algorithms to identify infections and JIA [26, 27] . We also used comprehensive pharmacy records and intervention procedure codes to examine exposure, although we could not confirm that the patients administered the medications as directed. A doseresponse relationship has been documented between use of CSs and higher risk of infection [44] . However, lack of information about children's weight and prescribers' tapering instructions resulted in considerable uncertainty in estimating the effect of the CS dose. In addition, because administrative data are not designed for research purposes, clinical data for health status in JIA (e.g. disease activity score and JIA subtype) were not available for analysis. Confounding from these and other unmeasured variables cannot be completely ruled out.
Specifically, an important unmeasured confounder in our study is the relationship between JIA itself and infection. JIA or RA was found to be associated with an increased risk of infection [31, 45, 46] , possibly because of T cell circulation and impaired thymic function [46, 47] . Our findings might have overestimated the TNFIinfection relationship if JIA severity was higher in the TNFI group. TNFIs are indicated for moderately to severely active polyarticular JIA, and thus children who receive TNFIs may have more severe JIA than those who receive DMARDs alone. Recognizing this possibility, we applied an hdPS approach using a large number of proxy indicators that indirectly reflected disease severity to account for the potential channelling bias. Several simulation studies have demonstrated the effectiveness of this method [28, 29] . Nonetheless, residual confounding of the JIAinfection relationship might remain.
Another potential limitation of our study is insufficient statistical power. Children with JIA constitute a smaller population than adults with RA. Although the rate of TNFI-related infection in our study was not extremely low, it is still challenging for any study to obtain a large enough sample size of children with JIA to examine safety outcomes adequately, especially in subgroup analyses. As a result, we could not perform analyses to evaluate the infection risk for individual TNFI agents and for combination therapy using TNFIs and CSs, nor could we conduct analyses using only the primary diagnosis in the inpatient claims for identifying patients with severe infection. In our analysis excluding patients with other rheumatic diseases and IBD, the risk of infection reduced toward the null. On the one hand, it is possible that IBD might confound the relationship between TNFIs and serious infection, because IBD patients were more likely to receive TNFI monotherapy and develop infections. On the other hand, the small number of observed infections yielded a wide 95% CI (0.28, 4.17), and we could not draw a conclusion with insufficient power in this analysis. Future studies are needed to examine the confounding effect of IBD and confirm our findings.
To facilitate studies of drug safety for children, it would be beneficial to incorporate relevant data into a nationalor international-scale surveillance system. As one example, the European registry called Pharmachild is a pharmacovigilance project that aims to observe longterm adverse events associated with use of DMARDs and biologics in children with JIA across 50 participating countries [48] . In the USA, the Childhood Arthritis and Rheumatology Research Alliance has initiated a prospective observational registry enrolling patients with paediatric rheumatic diseases across North America for research purposes, including research on long-term safety of medications [49] . Also, the FDA Sentinel Initiative is a national electronic surveillance system designed to monitor proactively and examine the safety of medications and biologics [50] . In future studies, use of data from such registries and systems would support a more thorough examination of potentially serious adverse events related to TNFIs.
Finally, the FDA-required black box warning might have impacted the observed association between TNFIs and infection. For example, physicians might have checked for infections more often in TNFI users than in DMARD users. In addition, the warning might have impacted the decision to admit to the hospital a patient with suspected infection differently depending on whether they were on TNFIs or DMARDs. Therefore, a differential detection or management bias might exist between the two exposure groups, which might have resulted in overestimation of relative risk in the TNFI group. In contrast, the FDA warning might have caused prescribers to avoid use of TNFIs for children susceptible to infection, and these children might have been channelled to DMARD treatment. In this case, our findings might have underestimated the relative risk in the TNFI group. However, we attempted to control for this type of confounding by applying contemporary analytical methods that included the hdPS modelling.
In summary, our study demonstrated a higher risk of serious bacterial infection associated with use of TNFIs compared with DMARDs in children with JIA. Our analysis supports the FDA warning about TNFI-associated infection in children with JIA and also provides a comparison between DMARD and TNFI monotherapy. Future studies incorporating a larger cohort of children with JIA would help to confirm our findings and further characterize the risk of infection across individual TNFI agents. In the meantime, clinicians and patients need to balance the benefits of these highly effective drugs against the risk for infection they pose.
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